India Generic Drug Maker Matrix Increases Stake in China's Mchem
This article was originally published in PharmAsia News
NEW DELHI - Hyderabad, India-based Matrix Laboratories has increased its stake in China-based Mchem group to 97 percent from 60 percent for an undisclosed amount, Matrix said
You may also be interested in...
Mylan Laboratories Inc., the number three generic drug producer in the world, is working to break into Japan's generic market. Recently Mylan bought out the generic end of Germany's Merck KGaA. The Merck deal gave Mylan control of subsidiaries selling generics in 90 countries around the world. Among these companies is the Japan-based Merck Seiyaku Ltd. Mylan plans to work with Seiyaku to expand its generic business across the country, especially production of slow-release formulas, Mylan's specialty. Seiyaku will also team up with India's Matric Laboratories Ltd., which is also an affiliate of Mylan. The two companies will work together to expand Matrix's active pharmaceutical ingredient business in Japan. (Click here for more
PharmAsia News looks ahead at 2015 to highlight expected trends and events shaping the biomedical community in Southeast Asia.
Southeast Asia in 2014 saw a continued push by several nations in the region to ink a Trans-Pacific Partnership pact that would potentially have a major impact on biological drugs. Also manufacturing and distribution saw a leap in the hub of Singapore as governments in the region ramped-up health spending.